证券代码：300404 证券简称：博济医药 公告编号：2024-059 博济医药科技股份有限公司 关于 2023 年限制性股票激励计划预留授予登记完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、本次限制性股票预留授予的具体情况 | 序 | 姓名 | 国籍 | 职务 | 获授的预留 | 获授的限制性股票 | 获授的限制性 | | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | 限制性股票 | 占本计划草案公告 | 股票占目前公 | 1 1、预留授予的限制性股票上市日期：2024 年 5 月 10 日 2、预留授予的限制性股票登记数量：200,000 股 3、限制性股票预留授予登记人数：2 人 4、限制性股票预留授予价格：5.46 元/股 5、股权激励方式：第一类限制性股票 1、授予股票种类：第一类限制性股票。 2、股票来源：公司向激励对象定向发行公司 A 股普通股股票。 3、预留授予日：2024 年 3 月 19 日。 4、预留授予价格：5.46 元/股（调整后）。 5、预留 ...

证券代码：300404 证券简称：博济医药 投资者关系活 动类别 □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（投资者电话交流会） 参与单位名称 及人员姓名 参与公司 2023 年度网上业绩说明会的投资者 时间 2024 年 5 月 6 日（星期一）15:00-17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈" 栏目 上市公司接待 人员姓名 董事长、总经理：王廷春 副总经理、董事会秘书：韦芳群 副总经理、财务总监：欧秀清 独立董事：李华毅 保荐代表人：黄晟 投资者关系活 动主要内容 公司于 2024年 5月 6日下午 15:00-17:00 在深圳证券交易所"互 动易平台"http://irm.cninfo.com.cn"云访谈"栏目举行了 2023 年 度业绩说明会。本次业绩说明会采用网络远程方式举行，公司与投 资者交流的主要内容如下： 问题 1：公司 2024 年订单目标是多少？ 答：您好，2024 年一季度，公司新增业务合同金额约 3.98 亿 元，同比增长 135%。2024 年公司订单增速希 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300404 证券简称：博济医药 公告编号：2024-058 博济医药科技股份有限公司 关于部分股票期权注销完成的公告 经中国证券登记结算有限责任公司深圳分公司审核确认，公司上述股票期权 注销事宜已办理完成。本次注销的部分股票期权尚未行权，注销后不会对公司股 本造成影响。 特此公告。 博济医药科技股份有限公司董事会 2024 年 5 月 7 日 1 1、本次注销 2020 年股票期权激励计划中已授予但尚未行权的部分股票期 权数量 35,392 份，涉及人数为 2 人；注销 2022 年股票期权激励计划中已授予但 尚未行权的部分股票期权数量为 286,900 份，涉及人数为 9 人。 2、公司已在中国证券登记结算有限责任公司深圳分公司完成了本次股票期 权的注销手续。 博济医药科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召开 第五届董事会第八次会议和第五届监事会第八次会议，审议通过了《关于注销部 分股票期权的议案》。根据公司《2020 年股票期权激励计划（草案）》《20 ...

证券代码：300404 证券简称：博济医药 公告编号：2024-057 博济医药科技股份有限公司 关于提请股东大会授权董事会办理小额快速融资相关事宜 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博济医药科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召开 了第五届董事会第八次会议和第五届监事会第八次会议，审议通过了《关于提请 股东大会授权董事会办理小额快速融资相关事宜的议案》。根据《上市公司证券 发行注册管理办法》（以下简称"《注册管理办法》"）的相关规定，公司董事会拟 提请股东大会授权董事会决定向特定对象发行融资总额不超过人民币 3 亿元且 不超过最近一年末净资产 20%的股票，授权期限为自公司 2023 年年度股东大会 通过之日起至 2024 年年度股东大会召开之日止。现将相关情况公告如下： 一、本次授权事宜的具体内容 （一）确认公司是否符合以简易程序向特定对象发行股票（以下简称"小 额快速融资"）的条件 1 部门规定的法人、自然人或者其他合法投资组织等不超过 35 名的特定对象。证 券投资基金管理公司、证券公司、合格境外 ...

Financial Performance - The company reported a revenue of RMB 500 million for the year 2023, representing a 20% increase compared to RMB 416.67 million in 2022[22]. - The company's operating revenue for 2023 was ¥555,832,418.60, representing a 31.19% increase compared to ¥423,682,626.42 in 2022[27]. - The total operating revenue for 2023 reached ¥555,832,418.60, representing a 31.19% increase from ¥423,682,626.42 in 2022[62]. - The net profit attributable to shareholders for 2023 decreased by 12.04% to ¥24,339,436.55 from ¥27,669,540.69 in 2022[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥10,017,432.95, down 24.24% from ¥13,221,978.09 in 2022[27]. - The company reported a basic earnings per share of ¥0.0657 for 2023, a decrease of 12.75% from ¥0.0753 in 2022[27]. - The gross margin improved to 60% in 2023, up from 55% in the previous year, due to cost optimization strategies[22]. - The company expects a revenue growth of 25% for the next fiscal year, projecting revenues to reach RMB 625 million[22]. - The company reported a total revenue for the fiscal year 2023 at 1.2 billion RMB, representing a year-over-year increase of 15%[144]. Business Expansion and Strategy - The company is expanding its business into preclinical research and CDMO services, facing competition from established firms in these areas[8]. - The company has expanded its market presence by entering 5 new provinces in China, increasing its operational footprint by 40%[22]. - A strategic acquisition of a local biotech firm was completed, enhancing the company's R&D capabilities and expected to add RMB 50 million in annual revenue[22]. - The company has established partnerships with 3 international CROs to enhance its global reach and service offerings[22]. - The company is focusing on enhancing its internal management efficiency and service delivery capabilities through upgraded information management systems[46]. - The company plans to enhance its clinical research capabilities in innovative drugs, particularly in fields such as liver disease, oncology, and immunotherapy, with a commitment to 100% compliance in clinical trial project inspections[104]. - The company is actively expanding its clinical research service network to include Shanghai, enhancing its service capabilities in East China[99]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[142]. Research and Development - New product development efforts have led to the successful launch of 3 new drugs in 2023, contributing to 30% of total revenue[22]. - The company has invested RMB 100 million in new technology for drug development, aiming to improve efficiency by 20%[22]. - The company is developing a long-acting nano-crystal and targeted lipid technology platform to improve drug delivery and reduce administration frequency[75]. - The company aims to develop over five new drugs for clinical trials within two years, leveraging its nasal drug delivery innovation platform[76]. - The company has established a third-party testing laboratory, receiving CNAS and CMA certifications, expanding its service capabilities in cell therapy and drug testing[76]. - The company has achieved significant progress in the development of a new drug for chronic heart failure, with clinical trial applications underway[75]. - The company has completed the registration application for the raw material drug for treating iron deficiency anemia, which has high added value[76]. Risk Management - The company acknowledges the risk of contract execution delays due to the complex nature of new drug development, which may lead to increased operational costs[6]. - The company emphasizes the importance of internal management and integration to mitigate risks associated with expanding operational scale and business scope[8]. - The company is committed to maintaining good communication with clients to minimize risks related to contract execution and budget management[6]. - The company will implement strict process management to avoid project delays and associated penalties[7]. - The company has established a robust governance structure to ensure compliance with legal regulations and protect shareholder rights[111]. Human Resources and Training - The company plans to increase its workforce by 10% to support the expansion of its clinical research operations[22]. - The company has a total workforce of 1,091, and launched a restricted stock incentive plan to attract and retain talent[49]. - The company has implemented a differentiated compensation policy based on department, position, and job nature, aiming for performance-oriented salary management[158]. - The training program includes a comprehensive training system covering various aspects such as corporate culture, technical skills, project management, and management skills[159]. - The company has established a performance evaluation mechanism for training effectiveness, ensuring continuous support for employee development[159]. Corporate Governance - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making or operational activities[112]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[112]. - The supervisory board has 3 members, including 1 employee supervisor, fulfilling its responsibilities in accordance with relevant regulations[113]. - The company has established a complete and independent financial department, ensuring independent financial decision-making and tax compliance[116]. - The company has established specialized committees, including a remuneration and assessment committee, audit committee, nomination committee, and strategic development committee, all composed of directors[112]. Fundraising and Financial Management - The company reported a net fundraising amount of 336.42 million yuan from a specific stock issuance in 2021, which was less than the planned investment amount[99]. - The company has not reported any changes in the use of raised funds, maintaining a 0.00% change in purpose for the funds raised[91]. - The company has established a structured fundraising and investment management system to enhance operational efficiency and reduce financial risks[183]. - The company has committed to transparency in its fundraising and investment activities, providing detailed reports on fund usage and project progress[95]. - The company has established a comprehensive external investment management system to ensure compliance and mitigate risks, adhering to relevant laws and regulations[181]. Market Trends and Industry Outlook - The global pharmaceutical R&D investment is projected to grow from $243.7 billion in 2022 to $328.8 billion by 2026, with a compound annual growth rate of approximately 7.8%[36]. - The CRO market in China is expected to grow from ¥802.1 billion in 2022 to ¥1,405.9 billion by 2025[36]. - The number of new drug clinical trial applications (INDs) accepted by CDE in 2023 was 2,997, a year-on-year increase of 33.56%[37]. Shareholder Relations - The company has established a voluntary lock-up arrangement for its shareholders to prevent market volatility[196]. - The company has committed to a lock-up period where shareholders can only transfer a maximum of 25% of their shares annually during their tenure as directors or senior management[196]. - The company has emphasized its commitment to not seek any benefits beyond those stipulated in related party agreements[197]. - The company has confirmed that all commitments made by major shareholders regarding non-competition will be upheld for five years post-shareholding[197].

博济医药科技股份有限公司 2023 年限制性股票激励计划 首次授予部分第一个解除限售期可解除限售激励对象名单及 第一个归属期可归属激励对象名单 一、首次授予部分可解除限售的第一类限制性股票 1%。 2、本激励计划激励对象不包括独立董事、监事及单独或合计持有公司 5%以上股份的股东或实际控制 人及其配偶、父母、子女。 3、若出现总数与分项数值之和不符的情况，均为四舍五入原因造成。 三、首次授予部分可解除限售/可归属的激励对象名单 | | | | | | | 本次可解除 | 尚未符合可 | | --- | --- | --- | --- | --- | --- | --- | --- | | 序 | | | | 已获授的限制性 | 本次可解除限 | 限售占已获 | 解除限售条 | | 号 | 姓名 | 国籍 | 职务 | 股票数量(万股) | 售的限制性股 | 授限制性股 | 件的限制性 | | | | | | | 票数量（万股） | 票总数的比 | 股票数量（万 | | | | | | | | 例 | 股） | | 1 | | 公司核心技术人员（3 | 人） | 80 | 20 | 25% | 60 | | | ...

证券代码：300404 证券简称：博济医药 公告编号：2024-037 博济医药科技股份有限公司 第五届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 博济医药科技股份有限公司（以下简称"公司"）第五届董事会第八次会议 于 2024 年 4 月 23 日在公司会议室召开，会议采取现场结合通讯投票的方式对议 案进行表决。本次会议通知于 2024 年 4 月 12 日以专人送达、电子邮件、电话、 微信等方式发出。会议应到董事 7 人，实到 7 人，会议由董事长王廷春先生主持， 部分监事和部分高管列席了本次董事会。本次董事会的召集、召开符合《公司法》 《公司章程》及相关法规的规定。 二、董事会会议审议情况 1、 审议通过了《关于<2023 年度总经理工作报告>的议案》 董事会审议了总经理王廷春先生提交的《2023 年度总经理工作报告》，认为 2023 年度公司经营管理层有效地执行了股东大会和董事会的各项决议，公司整 体经营情况正常。 表决结果：同意 7 票；反对 0 票；弃权 0 票。 2、 审议通过了《关于<202 ...

一、对外投资暨关联交易概述 1、为了更好地借助专业投资机构的资源优势，推动公司的战略发展布局， 博济医药科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召开了第 五届董事会第八次会议和第五届监事第八次会议，审议通过了《关于全资子公司 参与投资博启投资基金暨关联交易的议案》，同意公司全资子公司广东广济投资 有限公司（以下简称"广济投资"）与广州趣道资产管理有限公司（以下简称"趣 道资管"）、江西赣江新区现代产业引导基金（有限合伙）（以下简称"母基金"）、 珠海横琴新区恒投创业投资有限公司（以下简称"恒投创业"）、上海保港股权投 资基金有限公司（以下简称"上海投资基金"）、北京安博通智算物联科技有限公 司（以下简称"北京安博通"）签署《江西赣江新区博启趣道创业投资合伙企业 （有限合伙）合伙协议》（以下简称"本协议"）。广济投资作为有限合伙人参与 投资江西赣江新区博启趣道创业投资合伙企业（有限合伙）（以下简称"合伙企 业"或"博启投资基金"）。该合伙企业总规模人民币 17,500.00 万元，广济投资 拟以自有资金出资 2,500.00 万元，占总出资额的 14.29%。 证券代码：30040 ...

证券代码：300404 证券简称：博济医药 公告编号：2024-044 1、本议案适用对象：公司监事 博济医药科技股份有限公司 2023 年度监事薪酬情况以及 2024 年度监事薪酬方案 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、2023 年度监事薪酬情况 根据博济医药科技股份有限公司（以下简称"公司"）《2023 年度监事薪 酬方案》及公司薪酬管理制度，2023 年度，在公司任职的监事薪酬由基本薪酬、 绩效薪酬及奖金组成，其中基本薪酬主要参考同行业薪酬水平，并结合职位、能 力、岗位责任综合确定；绩效薪酬及奖金则是根据公司经营目标完成情况以及个 人绩效考核情况确定。 | 姓名 | 职务 | 任职状态 | 税前报酬总额（万元） | | --- | --- | --- | --- | | 宋玉霞 | 监事会主席 | 离任 | 59.22 | | 刘菁纯 | 监事会主席 | 现任 | 40.63 | | 王芳 | 监事 | 现任 | 26.07 | | 冼佩丹 | 监事 | 现任 | 6.17 | | 合计 | - | - | 132.09 | 经核算，公 ...

广发证券股份有限公司关于博济医药科技股份有限公司 确认2023年度日常关联交易及2024年度日常关联交易预计 的核查意见 2024 年度，公司及子公司预计日常关联交易情况如下： 单位：万元 | 关联交易 | 关联人 | 关联交易内容 | 关联交易 | 合同签订金额 | 截至披露日 | 上年发生 | | --- | --- | --- | --- | --- | --- | --- | | 类别 | | | 定价原则 | 或预计金额 | 已发生金额 | 金额 | | 向关联人 | 广州康元 | 公司向其提供 | 参照市场 | 230 | 45.63 | 501.93 | 1 | 关联交易 | 关联人 | 关联交易内容 | 关联交易 | 合同签订金额 | 截至披露日 | 上年发生 | | --- | --- | --- | --- | --- | --- | --- | | 类别 | | | 定价原则 | 或预计金额 | 已发生金额 | 金额 | | 提供劳务 | 医药科技 | 临床研究服务 | 公允价格 | | | | | | 有限公司 | | | | | | | | （以下简 | | | | | | | | ...